Radicava Oral Suspension, an oral formulation of edaravone, has been approved in Canada for treating amyotrophic lateral sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA), the subsidiary of Mitsubishi Tanabe Pharma America that markets Radicava in Canada, has announced plans to make the oral formula available to patients…
Starting treatment with riluzole earlier in the disease course could prolong overall survival for people with amyotrophic lateral sclerosis (ALS), a database study suggests. A one-year delay in beginning with riluzole may lower median survival by 1.9 months and a two-year delay by a median of 4.9 months, its…
Note: This story was updated Sept. 30, 2022, to correct the spelling of Albrioza and clarify the FDA advisory committee voted in March that the evidence from CENTAUR was not sufficient to support Relyvrio’s efficacy in ALS. It also added Relyvrio’s list price is set at about $158,000 per year.
As part of its Tribute Awards, the Muscular Dystrophy Association (MDA) will honor Alan Pestronk, MD, co-director of the MDA & ALS Care Center at Washington University School of Medicine. The Tribute Awards recognizes those “who have been tireless in their efforts” to support members of the neuromuscular disease…
The National Institutes of Health (NIH) has awarded $2.3 million to advance into testing an app that could improve how amyotrophic lateral sclerosis (ALS) is diagnosed, track the disease’s progression, and help assess a treatment’s effectiveness. The three-year Small Business Technology Transfer (STTR) grant was awarded to Modality.AI and…
After a two-year hiatus, the Muscular Dystrophy Association (MDA) is bringing back its in-person Wings Over Wall Street fundraiser gala in New York City, with proceeds going to support MDA research into promising amyotrophic lateral sclerosis (ALS) treatments. The June 9 event, starting at 6 p.m. EST at…
Silence ALS, a new initiative supported by Target ALS, set as its goals discovering and developing personalized antisense oligonucleotide (ASO) treatments for amyotrophic lateral sclerosis (ALS) patients with rare disease-causing mutations, while advancing understanding of the disease’s overall biology. The initiative, a collaboration between the n-Lorem Foundation, which…
In response to the National Institute of Neurological Disorders and Stroke‘s (NINDS) request for community input regarding what it should prioritize to accelerate amyotrophic lateral sclerosis (ALS) research, the ALS Association’s overarching message is this: move swiftly to help patients. NINDS, which is part of the National…
An Italian scientist was awarded $20,000 for research that may help pave the way for a TDP-43 antibody-based treatment for amyotrophic lateral sclerosis (ALS). The annual Paulo Gontijo Award from the Brazilian Paulo Gontijo Institute was granted to Silvia Tozzi, PhD, for her research, titled “Monoclonal full-length antibody…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Prilenia’s pridopidine for the treatment of amyotrophic lateral sclerosis (ALS). The decision follows a recent positive opinion from a branch of the European Medicines Agency recommending the treatment be given orphan drug status in…
Get regular updates to your inbox.